Liberal fluid intake was safe and suggestive of better health status: this should be enough to stop restricting patients to 1 ...

Additional research is needed to determine whether this is due to direct drug effects or underlying patient factors.

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

The prothrombin complex concentrate costs more than plasma, but may pay dividends by way of fewer adverse events.

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Despite the randomized trial showing a difference in outcomes, more data are needed before changing practice, says one expert ...

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

There are worries about delayed complications, but many places won’t get paid if AF patients don’t spend the night in ...

Findings from the first 500 patients treated with the Trilogy system met noninferiority for both safety and efficacy.